Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.54 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 16/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12783334 | 0.91 | SCN8A (0.57) | SCN3ASCN1BSCN8ASCN9ASCN5A | |
| SCHEMBL12783079 | 0.88 | SCN3A (0.57) | SCN3ASCN1BSCN8ASCN9ASCN5A | |
| SCHEMBL12783140 | 0.82 | SCN3A (0.58) | SCN3ASCN1BSCN8ASCN9ASCN5A | |
| SCHEMBL2075121 | 0.80 | AVPR2 (0.58) | SCN3ASCN1BSCN8ASCN9ASCN5A | |
| SCHEMBL12845878 | 0.80 | SCN1B (0.59) | SCN3ASCN1BSCN8ASCN9AMEN1 | |
| SCHEMBL12783493 | 0.79 | SCN3A (0.57) | SCN3ASCN8ASCN9ASCN5A | |
| SCHEMBL12783181 | 0.79 | SCN3A (0.65) | SCN3ASCN1BSCN8ASCN9ASCN5A | |
| SCHEMBL12783073 | 0.78 | SCN3A (0.59) | SCN3ASCN1BSCN8ASCN9ASCN5A | |
| SCHEMBL12782734 | 0.78 | SCN3A (0.73) | SCN3ASCN1BSCN8ASCN9ASCN5A | |
| SCHEMBL12782931 | 0.77 | SCN3A (0.84) | SCN3ASCN1BSCN8ASCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362032-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362032-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | CACNA1C, CACNA1B, CACNA1D | SCN3A 17/4885SCN1B 25/4885SCN8A 61/4885 |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | CACNA1C, CACNA1B, CACNA1D | SCN3A 17/4885SCN1B 25/4885SCN8A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.